Entera Bio Ltd
General ticker "ENTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $73.4M
Entera Bio Ltd follows the US Stock Market performance with the rate: 29.0%.
Estimated limits based on current volatility of 3.9%: low 2.02$, high 2.19$
Factors to consider:
- Current price 57.2% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.46$, 1.27$]
- 2024-12-30 to 2025-12-30 estimated range: [0.69$, 1.70$]
Financial Metrics affecting the ENTX estimates:
- Negative: Non-GAAP EPS, $ of -0.31 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -27.05 <= 2.35
- Positive: Interest expense per share, $ of 0 <= 0
Short-term ENTX quotes
Long-term ENTX plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $0.62MM | $0.18MM | $0.00MM |
Operating Expenses | $12.83MM | $13.20MM | $8.89MM |
Operating Income | $-12.22MM | $-13.02MM | $-8.89MM |
Non-Operating Income | $-0.03MM | $0.08MM | $0.03MM |
Interest Expense | $0.03MM | $0.00MM | $0.00MM |
R&D Expense | $6.77MM | $5.85MM | $4.51MM |
Income(Loss) | $-12.25MM | $-12.93MM | $-8.86MM |
Taxes | $-0.06MM | $0.14MM | $0.03MM |
Profit(Loss) | $-12.19MM | $-13.07MM | $-8.89MM |
Stockholders Equity | $22.57MM | $11.75MM | $10.39MM |
Inventory | $0.00MM | $0.29MM | $0.00MM |
Assets | $25.99MM | $13.13MM | $11.77MM |
Operating Cash Flow | $-9.06MM | $-12.50MM | $-7.31MM |
Capital expenditure | $0.02MM | $0.05MM | $0.02MM |
Investing Cash Flow | $-0.02MM | $-0.10MM | $-0.02MM |
Financing Cash Flow | $25.38MM | $0.01MM | $6.04MM |
Earnings Per Share* | $-0.47 | $-0.45 | $-0.31 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.